📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-31 16:42
12 analysed today
FollowTelegram
12
Today
151,456
All-time analysed
43,385
Positive
6,734
Negative
92,524
Neutral
8,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Hindustan Bio Sciences Approves Capital Reduction & Share Consolidation to Wipe Accumulated Losses
Hindustan Bio Sciences' Board approved a Scheme of Capital Reduction under Section 66 of the Companies Act to write off Rs 1.13 Cr of accumulated losses (out of total accumulated losses of Rs 1.22 Cr). The scheme reduces paid-up equity capital from Rs 2.05 Cr (1,02,50,800 shares of Rs 2 face value) to Rs 0.92 Cr (46,12,860 shares of Rs 2 face value) by cancelling 56,37,940 shares pro-rata. Subsequently, the remaining shares will be consolidated 5:1 from Rs 2 face value to Rs 10 face value, resulting in a final capital base of 9,22,572 equity shares of Rs 10 each (an effective ratio of 9 shares of Rs 10 for every 100 shares of Rs 2 held).
Confidence: HIGH
What changedBoard approved capital reduction and share consolidation, extinguishing 55% of shares to wipe off Rs 1.13 Cr of accumulated losses.
Why it mattersCleans up the balance sheet accumulated losses and adjusts capital structure, though fundamental business revenue (TTM Rs 0 Cr) and cash flows remain unchanged.
Existing Paid-up Capital: Rs. 2,05,01,600Proposed Paid-up Capital: Rs. 92,25,720Accumulated Losses Written Off: Rs. 1,12,75,880Total Accumulated Losses: Rs. 1,22,41,849Final Share Count (Rs 10 FV): 9,22,572 sharesConsolidation Ratio: 9 shares of Rs 10 for 100 shares of Rs 2
📅 Short termShare price and liquidity may see adjustments once NCLT approval is obtained and the record date for consolidation is fixed.
📈 Long termCapital restructuring cleans accumulated losses on the balance sheet, but long-term value creation depends entirely on reviving operational revenue and profitability.
⚠ Risk flags
- Scheme is subject to NCLT Hyderabad approval, which can take several months.
- Subdued core business fundamentals with negligible operational revenue.
Key Highlights
56,37,940 equity shares of Rs 2 face value will be cancelled and extinguished on a pro-rata basis.
Paid-up capital reduces from Rs 2,05,01,600 to Rs 92,25,720, setting off Rs 1,12,75,880 against accumulated losses of Rs 1,22,41,849.
Shares will be consolidated from Rs 2 to Rs 10 face value; shareholders will receive 9 equity shares of Rs 10 for every 100 shares of Rs 2 held.
Total outstanding shares shrink from 1,02,50,800 to 9,22,572 shares of Rs 10 each without altering relative percentage shareholding.
👀 What to Watch
Track shareholder approval at the upcoming AGM and subsequent NCLT Hyderabad bench approval timelines, followed by the record date announcement for share consolidation.
Hindustan Bio Sciences Reports Zero Revenue and Rs 11.29 Lakh Loss in Q1 FY27
Hindustan Bio Sciences reported a complete halt in operational revenue for the quarter ended June 30, 2026, recording Rs 0.00 compared to Rs 32.19 Lakhs in the same period last year. The company posted a net loss of Rs 11.29 Lakhs, a sharp decline from the Rs 1.40 Lakh profit recorded in Q1 FY26. Total expenses of Rs 11.29 Lakhs were primarily driven by employee benefits and administrative costs, despite no trading activity. With a high debt-to-equity ratio of 2.83 and very low promoter holding of 12.2%, the lack of revenue is a significant concern for solvency.
Confidence: HIGH
What changedThe company has moved from a marginally revenue-generating trading business to a state of zero operational income in the current quarter.
Why it mattersFor a micro-cap company with a market cap of only Rs 7 Cr and high debt (D/E 2.83), the absence of revenue makes it difficult to cover fixed costs like salaries and interest, increasing the risk of capital erosion.
Revenue (Q1 FY27): Rs 0.00 LakhsNet Loss (Q1 FY27): Rs 11.29 LakhsDebt-to-Equity Ratio: 2.83Promoter Holding: 12.19%Loss vs TTM Revenue: ~11.3%
📅 Short termThe stock is likely to face downward pressure as the market reacts to the total absence of revenue and widening losses.
📈 Long termThe long-term outlook remains highly speculative and risky given the inconsistent revenue history and extremely low promoter skin in the game.
⚠ Risk flags
- Zero operational revenue
- High debt-to-equity ratio of 2.83
- Very low promoter holding (12.19%)
- Negative net worth relative to debt levels
Key Highlights
Revenue from operations dropped to Rs 0.00 from Rs 32.19 Lakhs in the year-ago quarter
Net loss for the quarter stood at Rs 11.29 Lakhs versus a profit of Rs 1.40 Lakhs YoY
Employee benefit expenses remained steady at Rs 5.72 Lakhs despite zero revenue generation
The company's 34th Annual General Meeting (AGM) is scheduled for September 30, 2026
Total comprehensive loss for the period matched the net loss at Rs 11.29 Lakhs
👀 What to Watch
Investors should closely monitor the management's commentary during the upcoming AGM on September 30, 2026, regarding the resumption of pharmaceutical trading activities.
Hindustan Bio Sciences Reports Zero Revenue and Rs 11.29 Lakh Loss in Q1 FY27
Hindustan Bio Sciences reported a severe operational downturn for the quarter ended June 30, 2026, recording zero revenue from operations compared to Rs 32.19 lakhs in the same period last year. The company posted a net loss of Rs 11.29 lakhs, a sharp reversal from the Rs 1.40 lakhs profit in Q1 FY26. Total expenses of Rs 11.29 lakhs were primarily driven by employee benefits (Rs 5.72 lakhs) and other administrative costs. With a market cap of only Rs 7 Cr and a high debt-to-equity ratio of 2.83, the lack of revenue is a significant concern for solvency.
Confidence: HIGH
What changedThe company has moved from a marginally revenue-generating state to a zero-revenue state in Q1 FY27, leading to a net loss.
Why it mattersFor a micro-cap company with only Rs 1 Cr in annual revenue, a zero-revenue quarter suggests a total breakdown in business operations or trading cycles, threatening its survival given the high debt levels.
Revenue (Q1 FY27): Rs 0.00 lakhsNet Loss (Q1 FY27): Rs 11.29 lakhsRevenue vs TTM Revenue: 0%Debt-to-Equity Ratio: 2.83Promoter Holding: 12.19%
📅 Short termThe stock is likely to face downward pressure as the market reacts to the total absence of revenue and widening losses.
📈 Long termThe long-term outlook is highly risky given the inconsistent revenue, low promoter skin-in-the-game, and high leverage relative to net worth.
⚠ Risk flags
- Zero operational revenue in the current quarter
- High Debt-to-Equity ratio of 2.83
- Very low promoter holding at 12.19%
- Micro-cap status with limited liquidity
Key Highlights
Revenue from operations fell to Rs 0.00 lakhs from Rs 32.19 lakhs in the year-ago quarter
Net loss for the quarter stood at Rs 11.29 lakhs compared to a profit of Rs 1.40 lakhs YoY
Employee benefit expenses remained steady at Rs 5.72 lakhs despite zero revenue
The 34th Annual General Meeting (AGM) is scheduled for September 30, 2026
Company continues to operate in a single segment: Trading of Pharmaceuticals
👀 What to Watch
Investors should attend the AGM on September 30, 2026, to seek clarity on the complete halt in trading revenue and the company's plan to service its Rs 2 Cr debt with a dwindling net worth.
